Drug
LY2784544 clinical trials
Also written LY2784544.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
- LY2784544
- 2
Studies by the year they started
3 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Janus Kinase Inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses LY2784544 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of LY2784544 in Participants With Myeloproliferative NeoplasmsActive, not recruitingPhase 2Eli Lilly and CompanyNCT01594723Written as 120 mg LY2784544
- A Study in Myeloproliferative DisordersCompletedPhase 1Eli Lilly and CompanyNCT01134120Written as LY2784544
- Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsCompletedPhase 1Eli Lilly and CompanyNCT01520220Written as LY2784544